Eduardo Tolosa

List of Publications by Year
in descending order

117 papers	9,434 citations	66250 44 h-index	48101 92 g-index
120 all docs	120 docs citations	120 times ranked	10506 citing authors

#	Article	IF	Citations
1	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. Journal of Neurology, 2022, 269, 1335-1352.	1.8	23
2	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	1.5	21
3	Differential Phosphoâ€Signatures in Blood Cells Identify <scp>LRRK2 G2019S</scp> Carriers in Parkinson's Disease. Movement Disorders, 2022, 37, 1004-1015.	2.2	9
4	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	2.2	15
5	New spinocerebellar ataxia subtype caused bySAMD9Lmutation triggering mitochondrial dysregulation (SCA49). Brain Communications, 2022, 4, fcac030.	1.5	15
6	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	2.2	222
7	The Interaction between <scp>HLAâ€DRB1</scp> and Smoking in Parkinson's Disease Revisited. Movement Disorders, 2022, 37, 1929-1937.	2.2	4
8	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	1.5	16
9	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinsonâ€™s disease. Sleep, 2021, 44, .	0.6	16
10	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain, 2021, 144, 1118-1126.	3.7	92
11	Impaired cerebral microcirculation in isolated REM sleep behaviour disorder. Brain, 2021, 144, 1498-1508.	3.7	6
12	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. Parkinsonism and Related Disorders, 2021, 86, 124-132.	1.1	22
13	Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder. Npj Parkinson's Disease, 2021, 7, 40.	2.5	9
14	Native Î±-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-Î±-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinsonâ€™s Disease. Antioxidants, 2021, 10, 715.	2.2	12
15	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	2.8	30
16	Challenges in the diagnosis of Parkinson's disease. Lancet Neurology, The, 2021, 20, 385-397.	4.9	468
17	R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathologica, 2021, 142, 475-494.	3.9	44
18	The Parkinsonâ€™s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinsonâ€™s Disease in Patients and their Carers. Journal of Parkinson's Disease, 2021, 11, 1309-1323.	1.5	8

#	Article	IF	Citations
19	Consensus on the treatment of dysphagia in Parkinson's disease. Journal of the Neurological Sciences, 2021, 430, 120008.	0.3	23
20	Dopamine transporter imaging predicts clinicallyâ€defined Î±â€synucleinopathy in REM sleep behavior disorder. Annals of Clinical and Translational Neurology, 2021, 8, 201-212.	1.7	37
21	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. Frontiers in Neurology, 2021, 12, 754016.	1.1	7
22	Transcriptome analysis in LRRK2 and idiopathic Parkinsonâ€™s disease at different glucose levels. Npj Parkinson's Disease, 2021, 7, 109.	2.5	1
23	Nonsteroidal <scp>Antiâ€inflammatory</scp> Use and <scp>LRRK2</scp> Parkinson's Disease Penetrance. Movement Disorders, 2020, 35, 1755-1764.	2.2	57
24	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. Parkinsonism and Related Disorders, 2020, 81, 89-93.	1.1	14
25	LRRK2 in Parkinson disease: challenges of clinical trials. Nature Reviews Neurology, 2020, 16, 97-107.	4.9	281
26	Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers. Journal of Neurology, 2020, 267, 2296-2300.	1.8	18
27	Emergencies and critical issues in Parkinsonâ€™s disease. Practical Neurology, 2019, 20, practneurol-2018-002075.	0.5	19
28	Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. Parkinsonism and Related Disorders, 2019, 66, 87-93.	1.1	21
29	Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Movement Disorders, 2019, 34, 1392-1398.	2.2	28
30	Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease. EBioMedicine, 2019, 48, 554-567.	2.7	28
31	Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease. Stem Cell Reports, 2019, 12, 213-229.	2.3	250
32	Stridor in multiple system atrophy. Neurology, 2019, 93, 630-639.	1.5	86
33	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	2.2	73
34	Co-morbid demyelinating lesions and atypical clinical features in a patient with Parkinson's disease. Parkinsonism and Related Disorders, 2019, 62, 242-245.	1.1	2
35	Simultaneous low-frequency deep brain stimulation of the substantia nigra pars reticulata and high-frequency stimulation of the subthalamic nucleus to treat levodopa unresponsive freezing of gait in Parkinson's disease: A pilot study. Parkinsonism and Related Disorders, 2019, 60, 153-157.	1.1	59
36	GBA mutation promotes early mitochondrial dysfunction in 3D neurosphere models. Aging, 2019, 11, 10338-10355.	1.4	15

#	Article	IF	Citations
37	Î±â€synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucineâ€rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. Movement Disorders, 2018, 33, 637-641.	2.2	25
38	An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2018, 125, 953-963.	1.4	18
39	Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2018, 50, 94-98.	1.1	23
40	Clustering of motor and nonmotor traits in leucineâ€rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. Movement Disorders, 2018, 33, 960-965.	2.2	12
41	Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiology of Disease, 2018, 115, 9-16.	2.1	35
42	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. Movement Disorders, 2018, 33, 1528-1539.	2.2	73
43	Expanding the ADCY5 phenotype toward spastic paraparesis. Neurology: Genetics, 2018, 4, e214.	0.9	11
44	Lack of pathogenic potential of peripheral Î±-synuclein aggregates from Parkinsonâ€™s disease patients. Acta Neuropathologica Communications, 2018, 6, 8.	2.4	19
45	Myoclonusâ€•D ominant C orticobasal D egeneration. Movement Disorders Clinical Practice, 2018, 5, 649-652.	0.8	1
46	MAPT association with REM sleep behavior disorder. Neurology: Genetics, 2017, 3, e131.	0.9	10
47	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinsonâ€™s disease treated with L-DOPA. Expert Review of Neurotherapeutics, 2017, 17, 649-659.	1.4	11
48	The prodromal phase of leucineâ€rich repeat kinase 2â€“associated Parkinson disease: Clinical and imaging Studies. Movement Disorders, 2017, 32, 726-738.	2.2	48
49	Aggregation of Î±-Synuclein in the Gonadal Tissue of 2 Patients With Parkinson Disease. JAMA Neurology, 2017, 74, 606.	4.5	10
50	Penetrance estimate of LRRK2 p.G2019S mutation in individuals of nonâ€Ashkenazi Jewish ancestry. Movement Disorders, 2017, 32, 1432-1438.	2.2	126
51	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurology, The, 2017, 16, 789-796.	4.9	155
52	Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. Neurobiology of Aging, 2017, 50, 167.e11-167.e13.	1.5	24
53	Caveats of Neurodegenerative Risk Stratification in Idiopathic REM Sleep Behavior Disorder by Use of the MDS Research for Prodromal Parkinsonâ€™s Disease. Sleep, 2017, 40, .	0.6	5
54	A Novel p.Glu298Lys Mutation in the ACMSD Gene in Sporadic Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 459-463.	1.5	15

#	Article	IF	Citations
55	Two-hundred Years Later: Is Parkinsonï¿½s Disease a Single Defined Entity?. Revista De Investigacion Clinica, 2017, 69, 308-313.	0.2	4
56	Inflammatory profile in LRRK2-associated prodromal and clinical PD. Journal of Neuroinflammation, 2016, 13, 122.	3.1	57
57	Motor and nonmotor heterogeneity of LRRK2â€related and idiopathic Parkinson's disease. Movement Disorders, 2016, 31, 1192-1202.	2.2	102
58	DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2â€‰R1441G Parkinson's disease. Movement Disorders, 2016, 31, 335-343.	2.2	33
59	Cerebrospinal fluid biomarkers and clinical features in leucineâ€rich repeat kinase 2 (LRRK2) mutation carriers. Movement Disorders, 2016, 31, 906-914.	2.2	29
60	Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibilityâ€weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Annals of Neurology, 2016, 79, 1026-1030.	2.8	90
61	Assessment of Î±-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurology, The, 2016, 15, 708-718.	4.9	145
62	Update on the Diagnosis and Management of Progressive Supranuclear Palsy. Current Geriatrics Reports, 2016, 5, 85-94.	1.1	0
63	Nigral and striatal connectivity alterations in asymptomaticLRRK2mutation carriers: A magnetic resonance imaging study. Movement Disorders, 2016, 31, 1820-1828.	2.2	45
64	White matter hyperintensities, cerebrospinal amyloid-Î² and dementia in Parkinson's disease. Journal of the Neurological Sciences, 2016, 367, 284-290.	0.3	26
65	Total Î±-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA. Analytical and Bioanalytical Chemistry, 2016, 408, 7669-7677.	1.9	22
66	Arm swing as a potential new prodromal marker of Parkinson's disease. Movement Disorders, 2016, 31, 1527-1534.	2.2	136
67	Challenges of modifying disease progression in prediagnostic Parkinson's disease. Lancet Neurology, The, 2016, 15, 637-648.	4.9	78
68	Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurology, The, 2016, 15, 405-419.	4.9	199
69	Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder. Neurology, 2016, 86, 1072-1073.	1.5	30
70	Aberrant epigenome in <scp>iPSC</scp> â€derived dopaminergic neurons from Parkinson's disease patients. EMBO Molecular Medicine, 2015, 7, 1529-1546.	3.3	117
71	Disclosure of research results in genetic studies of Parkinson's disease caused by LRRK2 mutations. Movement Disorders, 2015, 30, 904-908.	2.2	8
72	Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	4.5	272

#	Article	IF	Citations
73	Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism and Related Disorders, 2015, 21, 871-876.	1.1	79
74	Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology, 2015, 84, 654-658.	1.5	164
75	Peripheral synuclein tissue markers: a step closer to Parkinsonâ€™s disease diagnosis: Figure 1. Brain, 2015, 138, 2120-2122.	3.7	14
76	Cystatin <scp>C</scp> is differentially involved in multiple system atrophy phenotypes. Neuropathology and Applied Neurobiology, 2015, 41, 507-519.	1.8	7
77	Enteric nervous system Î±-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology, 2015, 85, 1761-1768.	1.5	121
78	Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. Parkinsonism and Related Disorders, 2015, 21, 1170-1176.	1.1	43
79	Nonmotor Symptoms in LRRK2 G2019S Associated Parkinsonâ€™s Disease. PLoS ONE, 2014, 9, e108982.	1.1	79
80	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open, 2014, 4, e005122-e005122.	0.8	35
81	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. Genetics in Medicine, 2014, 16, 644-645.	1.1	7
82	A phase 2 trial of the GSKâ€3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders, 2014, 29, 470-478.	2.2	251
83	Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial. Parkinsonism and Related Disorders, 2014, 20, 640-643.	1.1	35
84	Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinsonâ€™s disease experiencing mild wearing-off: a randomised, double-blind trial. Journal of Neural Transmission, 2014, 121, 357-366.	1.4	23
85	Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan). Journal of Nuclear Medicine, 2014, 55, 1281-1287.	2.8	19
86	Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using ¹²³I-Ioflupane Injection (DaTscan) Imaging. Journal of Nuclear Medicine, 2014, 55, 1288-1296.	2.8	17
87	Progress in defining the premotor phase of Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 4-8.	0.3	47
88	Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurology, The, 2011, 10, 797-805.	4.9	293
89	Reply: Rapidly progressing diffuse Lewy body disease. Movement Disorders, 2011, 26, 2585-2585.	2.2	0
90	Premotor Parkinson disease. Neurology, 2009, 72, S1.	1.5	267

#	Article	IF	Citations
91	Diagnosis and the premotor phase of Parkinson disease. Neurology, 2009, 72, S12-20.	1.5	210
92	Red flags for multiple system atrophy. Movement Disorders, 2008, 23, 1093-1099.	2.2	215
93	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	4.9	1,340
94	Accuracy of DaTSCAN (¹²³Iâ€ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2â€Year followâ€up of an openâ€label study. Movement Disorders, 2007, 22, 2346-2351.	2.2	108
95	Movement disorders: advances on many fronts. Lancet Neurology, The, 2007, 6, 7-8.	4.9	5
96	Dementia in Parkinson's disease. Journal of Neurology, 2007, 254, 41-48.	1.8	8
97	LRRK2 Mutations in Spanish Patients With Parkinson Disease. Archives of Neurology, 2006, 63, 377.	4.9	127
98	Dystonia in Parkinsonâ€™s disease. Journal of Neurology, 2006, 253, vii7-vii13.	1.8	116
99	The diagnosis of Parkinson's disease. Lancet Neurology, The, 2006, 5, 75-86.	4.9	665
100	Caribbean parkinsonism and other atypical Parkinsonian disorders. Parkinsonism and Related Disorders, 2004, 10, S19-S26.	1.1	4
101	Cognitive effects of unilateral posteroventral pallidotomy: A 4-year follow-up study. Movement Disorders, 2003, 18, 323-328.	2.2	11
102	DAT imaging in drug-induced and psychogenic parkinsonism. Movement Disorders, 2003, 18, S28-S33.	2.2	97
103	Systemic Administration of NMDA and AMPA Receptor Antagonists Reverses the Neurochemical Changes Induced by Nigrostriatal Denervation in Basal Ganglia. Journal of Neurochemistry, 2002, 73, 344-352.	2.1	47
104	Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. Annals of Neurology, 2001, 49, 263-267.	2.8	173
105	Eye opening in brain death. Journal of Neurology, 1999, 246, 720-722.	1.8	24
106	Stiff-man syndrome with vacuolar degeneration of anterior horn motor neurons. Journal of Neurology, 1999, 246, 858-860.	1.8	39
107	Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Annals of Neurology, 1999, 46, 774-777.	2.8	103
108	The eye of the tiger sign in cortical-basal ganglionic degeneration. Movement Disorders, 1999, 14, 169-171.	2.2	43

#	Article	IF	Citations
109	Cognitive and behavioral changes after unilateral posteroventral pallidotomy: Relationship with lesional data from MRI. Movement Disorders, 1999, 14, 780-789.	2.2	46
110	Stiff-leg syndrome: A focal form of stiff-man syndrome. Annals of Neurology, 1998, 43, 400-403.	2.8	62
111	Biochemical and molecular effects of chronic haloperidol administration on brain and muscle mitochondria of rats. Journal of Neuroscience Research, 1998, 53, 475-481.	1.3	30
112	Cerebellar Cortex Delayed Maturation in Sudden Infant Death Syndrome. Journal of Neuropathology and Experimental Neurology, 1997, 56, 340-346.	0.9	48
113	Ictal Laughter Associated with Paroxysmal Hypothalamopituitary Dysfunction. Epilepsia, 1997, 38, 114-117.	2.6	70
114	Cervical and facial myoclonus associated with dolichoectasia of the left vertebral artery. Movement Disorders, 1997, 12, 790-793.	2.2	15
115	Regional cerebral blood flow pattern in normal young and aged volunteers: a99mTc-HMPAO SPET study. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1329-1337.	2.2	81
116	Striatal c-fos levels do not correlate with haloperidol-induced behavioral supersensitivity. , 1996, 23, 89-93.		11
117	Blink reflex studies in focal dystonias: Enhanced excitability of brainstem interneurons in cranial dystonia and spasmodic torticollis. Movement Disorders, 1988, 3, 61-69.	2.2	166